New Weight Loss Drugs May Fight Obesity-Related Cancer, Too
Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.
'Probably going to be the most prescribed drug'; The future of weight loss drugs
Drugs like Ozempic, Wegovy and Mounjaro are changing the game for weight loss.  GLP-1 medications were originally intended to treat type 2 diabetes, but a growing number of people are using it for weight loss.
Can weight loss drugs curb alcohol addictions? New research looks at the possibility.
Can weight loss drugs curb alcohol addictions? This Louisiana doctor is keeping an eye on new findings and emerging research.
7 facts about this weight loss drugs that actually work
Research reveals groundbreaking results about Mounjaro and Ozempic in weight loss treatment. Here's what you need to know about these game-changing medications.
Eli Lilly’s stock falls as weight-loss drug sales disappoint
Shares of Eli Lilly and Co. slipped 0.4% in premarket trading Tuesday, after the drug maker provided a disappointing fourth-quarter revenue outlook, citing slower-than-expected growth in sales of its weight-loss drugs.
Eli Lilly CEO expects new weight loss pill to be approved next year
Eli Lilly and its rivals are working to develop more convenient options than the injectable Zepbound and Wegovy, which dominate the weight loss drug market.
Eli Lilly Stumbled But Weight-Loss Drugs Will Continue to Fuel Markets. Here’s Why and 5 Other Things to Know Today.
SEC sues Elon Musk over Twitter purchase, Microsoft says businesses should get quantum ready in 2025, and more news to start your day.
Eli Lilly was hoping weight loss drug demand would be even bigger
Eli Lilly (LLY) revised its revenue outlook on Tuesday for the fourth quarter of 2024 on weaker-than-expected demand for its popular weight-loss drugs, Zepbound and Mounjaro.
Eli Lilly shares drop as drugmaker cuts revenue guidance on weight loss drug demand
Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.
Hims & Hers in focus as Eli Lilly obesity drug sales disappoint
Eli Lilly (NYSE:LLY) shares sold off on Tuesday after the Indiana-based pharma giant's Q4 and 2024 preliminary sales results for its obesity therapy tirzepatide fell short of Street forecasts. Novo Nordisk (NVO),
The Next Web5d
Verdiva launches with $410M for weight loss drugs to challenge Ozempic, Wegovy
The round is one of Europe’s largest-ever biotech VC deals, signalling investor appetite for the booming weight loss market.
MadameNoire2d
Ozempic 2.0? New Experimental Weight Loss Drug Helps Patients Shed Fat Faster, Study
Eli Lilly's experimental weight loss drug, retatrutide, has demonstrated encouraging results in helping obese adults lose weight.
FOX News on MSN10d
Ozempic ‘microdosing’ is the new weight-loss trend: Should you try it?
A new trend gaining popularity among people trying to lose ... more people are turning to weight loss medications to ...
NY Governor unveils plan to expand healthcare coverage for weight loss drugs
On Tuesday, New York Governor Kathy Hochul announced a new initiative to expand access to healthcare coverage for popular ...